- Home
- IVVD vs VTGN Comparison
IVVD vs VTGN Comparison
Compare IVVD & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- VTGN
- Stock Information
- Founded
- IVVD 2020
- VTGN 1998
- Country
- IVVD United States
- VTGN United States
- Employees
- IVVD N/A
- VTGN N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- VTGN Biotechnology: Pharmaceutical Preparations
- Sector
- IVVD Health Care
- VTGN Health Care
- Exchange
- IVVD Nasdaq
- VTGN Nasdaq
- Market Cap
- IVVD 69.0M
- VTGN 70.0M
- IPO Year
- IVVD 2021
- VTGN N/A
- Fundamental
- Price
- IVVD $0.75
- VTGN $2.13
- Analyst Decision
- IVVD Strong Buy
- VTGN
- Analyst Count
- IVVD 3
- VTGN 0
- Target Price
- IVVD $5.85
- VTGN N/A
- AVG Volume (30 Days)
- IVVD 1.8M
- VTGN 163.8K
- Earning Date
- IVVD 08-13-2025
- VTGN 06-17-2025
- Dividend Yield
- IVVD N/A
- VTGN N/A
- EPS Growth
- IVVD N/A
- VTGN N/A
- EPS
- IVVD N/A
- VTGN N/A
- Revenue
- IVVD $36,688,000.00
- VTGN $486,000.00
- Revenue This Year
- IVVD $446.60
- VTGN N/A
- Revenue Next Year
- IVVD $112.63
- VTGN N/A
- P/E Ratio
- IVVD N/A
- VTGN N/A
- Revenue Growth
- IVVD N/A
- VTGN N/A
- 52 Week Low
- IVVD $0.35
- VTGN $1.90
- 52 Week High
- IVVD $2.74
- VTGN $4.21
- Technical
- Relative Strength Index (RSI)
- IVVD 43.27
- VTGN 35.75
- Support Level
- IVVD $0.70
- VTGN $2.18
- Resistance Level
- IVVD $1.03
- VTGN $2.44
- Average True Range (ATR)
- IVVD 0.07
- VTGN 0.15
- MACD
- IVVD -0.03
- VTGN -0.03
- Stochastic Oscillator
- IVVD 12.75
- VTGN 1.89
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.